Bruker (NASDAQ:BRKR) Shares Gap Down After Earnings Miss

Bruker Corporation (NASDAQ:BRKR) shares gapped down before the market opened on Thursday following a weaker than expected earnings announcement. The stock had previously closed at $42.43, but opened at $39.16. Bruker shares last traded at $38.5980, with a volume of 920,030 shares trading hands.

The medical research company reported $0.59 earnings per share for the quarter, missing the consensus estimate of $0.65 by ($0.06). The firm had revenue of $977.20 million for the quarter, compared to analysts’ expectations of $964.61 million. Bruker had a negative net margin of 0.61% and a positive return on equity of 15.45%. Bruker’s revenue for the quarter was down .2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.76 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS.

Key Headlines Impacting Bruker

Here are the key news stories impacting Bruker this week:

• Positive Sentiment: Revenue beat — Bruker reported Q4 revenue of $977.2M vs. consensus ~$964.6M, showing a modest upside on sales that may support valuation upside if margin trends improve. Bruker Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: FY‑2026 revenue guide above Street — management guided FY‑2026 revenue to about $3.6B (vs. consensus ~$3.5B), which is constructive for growth expectations and could support longer‑term multiple expansion if profitability improves. Bruker Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Partnership expansion — Bruker announced a Premas Life Sciences partnership in India (spatial biology), which could help commercial penetration in a large market and drive incremental equipment and consumables revenue over time. Premas Life Sciences Partners with Bruker Spatial Biology
• Neutral Sentiment: Short‑interest data appears unreliable — multiple feeds show “0 shares” and NaN changes; no meaningful short‑interest signal can be derived from the published entries. This reduces the likelihood that a short squeeze or coordinated shorting is driving moves. (Data anomaly.)
• Neutral Sentiment: Company released slide deck and hosted conference call — investors can review management’s detail on margins, backlog and segment outlook to reassess the move; these materials may clarify guidance assumptions. View Press Release / Slide Deck
• Negative Sentiment: EPS miss and declining per‑share results — Q4 EPS was $0.59 vs. consensus ~$0.65 and vs. $0.76 a year ago; earnings weakness and year‑over‑year EPS decline are principal drivers of the negative stock reaction. Bruker (BRKR) Q4 Earnings Miss Estimates
• Negative Sentiment: EPS guidance touches investor nerves — FY‑2026 EPS guidance of $2.10–$2.15 has a midpoint ~2.125, slightly below consensus (~2.13). Even with revenue guidance above Street, the lower EPS midpoint suggests near‑term margin pressure or incremental costs, which ratcheted down sentiment. Bruker Reports Fourth Quarter and Full Year 2025 Financial Results
• Negative Sentiment: Profitability softness — Q4 showed a negative net margin (~‑0.6%) despite positive ROE; persistent margin pressure will keep investors cautious until free‑cash‑flow and margin recovery are visible. MarketBeat Earnings Summary

Wall Street Analyst Weigh In

A number of research firms have commented on BRKR. Wolfe Research raised Bruker from a “peer perform” rating to an “outperform” rating and set a $60.00 price target on the stock in a report on Wednesday, December 10th. JPMorgan Chase & Co. lifted their target price on Bruker from $50.00 to $55.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Guggenheim upped their price target on Bruker from $53.00 to $58.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. TD Cowen reaffirmed a “hold” rating on shares of Bruker in a report on Wednesday, January 7th. Finally, Wells Fargo & Company boosted their target price on shares of Bruker from $48.00 to $55.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, five have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $52.46.

Insider Buying and Selling at Bruker

In related news, VP Mark Munch sold 7,000 shares of the stock in a transaction on Monday, January 12th. The stock was sold at an average price of $55.00, for a total transaction of $385,000.00. Following the sale, the vice president owned 128,443 shares in the company, valued at approximately $7,064,365. This represents a 5.17% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 27.30% of the company’s stock.

Institutional Investors Weigh In On Bruker

Several hedge funds and other institutional investors have recently made changes to their positions in BRKR. Nisa Investment Advisors LLC grew its holdings in Bruker by 377.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 487 shares during the last quarter. Los Angeles Capital Management LLC purchased a new position in shares of Bruker during the fourth quarter valued at approximately $26,000. Allworth Financial LP grew its stake in shares of Bruker by 40.6% during the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after buying an additional 257 shares during the last quarter. Huntington National Bank raised its holdings in shares of Bruker by 750.0% in the second quarter. Huntington National Bank now owns 731 shares of the medical research company’s stock worth $30,000 after buying an additional 645 shares during the period. Finally, Spire Wealth Management bought a new stake in shares of Bruker during the 2nd quarter worth approximately $32,000. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Bruker Trading Down 11.6%

The stock has a fifty day moving average of $47.15 and a 200-day moving average of $40.55. The company has a market cap of $5.70 billion, a PE ratio of -234.44, a PEG ratio of 5.58 and a beta of 1.19. The company has a debt-to-equity ratio of 0.81, a quick ratio of 0.91 and a current ratio of 1.85.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.